| Objective : To study the effects of rh-BNP(recombinant human brain natriuretic peptide)in combination with levosimendan treatment on clinical outcomes,adverse effects,and the occurrence of MACE(major adverse cardiac events)in patients with HFr EF.Methods:A total of 67 patients with heart failure with decreased ejection fraction admitted to the Department of Cardiovascular Medicine of the Second Clinical College of Medicine,Inner Mongolia University for Nationalities from May 2021 to June 2022 were included and randomly divided into rh-BNP group and rh-BNP combined with Leveo-Siemendan group.Both groups were treated with conventional anti-heart failure drugs.On this basis,rh-BNP group was given rh-BNP treatment,and rh-BNP combined with levosimendan group was given rh-BNP combined with levosimendan treatment.After medication,systolic blood pressure,diastolic blood pressure,heart rate,clinical efficacy,laboratory indicators(NT-pro BNP,hs-c Tn T,D-dimer,CRP)and cardiac function indicators(LVESD,LVEDD,LVEF,SV),adverse reactions,and the incidence of MACE within 6 months were compared between the two groups before and after treatment.Results:(1)Before treatment,there was no statistically significant difference in the basic data of the two groups: gender,age,body mass index,admission cardiac function grade,patients with basic heart disease,other diseases combined(such as hypertension,diabetes,pulmonary infection)and basic medication(P >0.05).(2)Comparison between the two groups after treatment and before treatment: Systolic blood pressure,diastolic blood pressure,heart rate,NT-pro BNP,hs-c Tn T,D-dimer,CRP,LVESD and LVEDD were all lower than before treatment,while LVEF and SV were higher,the difference was statistically significant(P<0.05).(3)There was no significant difference in systolic blood pressure,diastolic blood pressure and heart rate between the two groups after treatment(P >0.05);The total effective rate of rh-BNP combined with levosimendan group(86%)was higher than that of rh-BNP group(63%),and the difference was statistically significant(P<0.05).The NT-pro BNP,hs-c Tn T,D-dimer and CRP of rh-BNP combined with Levosimendan group were lower than those of rh-BNP group,and the difference was statistically significant(P<0.05).LVESD and LVEDD of rh-BNP combined with Levosimendan group were lower than those of rh-BNP group,and the difference was statistically significant(P<0.05).LVEF and SV of rh-BNP combined with Levosimendan group were higher than those of rh-BNP group,and the difference was statistically significant(P<0.05).(4)There was no statistical significance in the incidence of adverse reactions between rh-BNP group(6%)and rh-BNP combined with levosimendan group(9%)(P >0.05).(5)Within 6 months of follow-up,the incidence of MACE events in rh-BNP combined with levosimendan group(25.8%)was lower than that in rh-BNP group(50%),the difference was statistically significant(P<0.05).The survival rate of rh-BNP combined with levosimendan group was higher than that of rh-BNP group(Log-Rank P<0.05).Conclusions:rh-BNP alone versus rh-BNP combined with levosimendan was safe and effective in treating HFr EF.rh-BNP combined with levosimendan had better efficacy,less incidence of MACE,the survival rate was higher than rh-BNP group. |
PDF Full Text Request